Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 May;62(3):349-51.
doi: 10.1023/a:1023396020559.

Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases

Affiliations

Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases

B Benyahia et al. J Neurooncol. 2003 May.

Abstract

Sera from 71 patients with primary Sjögren's syndrome (PSS) and from 102 patients with systemic lupus erythematosus (SLE) were tested by immuno-dot blotting against HuD, Ri, Yo and amphiphysin recombinant proteins. For Ri, Yo and amphiphysin antigens, no immunoreactivity was found in the 173 sera tested. One PSS patient with a clinical picture of subacute sensory neuronopathy had high titers of anti-Hu antibodies. An extensive search for an underlying tumor was initially negative but a small cell lung cancer was eventually discovered three years later. Another patient with SLE and a clinical picture of demyelinating polyradiculoneuropathy had anti-Hu antibodies. Repeated search for an underlying tumor remains negative after five years follow-up in this young non-smoking patient. In addition, the neuropathy progressively improved and the anti-Hu antibodies titer slowly decreased from 1:8000 to 1:2000, making the diagnosis of paraneoplastic syndrome unlikely in this patient. This study indicates that the detection of anti-Hu antibodies in patients with known symptomatic systemic autoimmune diseases such as PSS or SLE should induce the same work-up than the detection of these antibodies in the absence of other immune diseases, i.e. repeated search for occult cancer during several years. As illustrated by our first patient, this strategy may be fruitful. Nevertheless, the clinician should know that anti-Hu antibodies may exceptionally (0.6% in this series) occur in systemic autoimmune disorders with neurological complications, in the absence of an underlying neoplastic disease.

PubMed Disclaimer

References

    1. Arthritis Rheum. 1997 Sep;40(9):1725 - PubMed
    1. J Neurol Neurosurg Psychiatry. 1997 Mar;62(3):276-8 - PubMed
    1. Neurology. 2001 Aug 14;57(3):558-9 - PubMed
    1. J Clin Neurophysiol. 1999 Mar;16(2):164-8 - PubMed
    1. Medicine (Baltimore). 1982 Jul;61(4):247-57 - PubMed

MeSH terms

LinkOut - more resources